Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a fruit acid in tiny carriers rival steroid creams for psoriasis?

NCT ID NCT07816575

Symptom relief Sponsor: Al-Azhar University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers compare alpha hydroxy acids, both with and without nanocarriers, against a standard calcipotriol plus betamethasone ointment for plaque psoriasis. The trial enrolls 80 adults with mild to moderate psoriasis who have not used psoriasis therapy for two months. Participants apply treatments to their plaques, and researchers measure changes in psoriasis severity and quality of life over eight weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
alpha hydroxy acids, with and without nanocarriers
What this could lead to
If the nanocarrier version works, it could offer a non-steroidal option for long-term plaque psoriasis management.
What could go wrong
This is a small, early study. Alpha hydroxy acids can irritate skin, and the results may not hold up in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Mar 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:- Mid to moderate cases according to Psoriasis Area and Severity Index (PASI). * Age from18-65 years old. * Denovo psoriatic patients and patients with no psoriasis therapy in the previous two months. Exclusion Criteria: * Severe irritation and highly inflamed skin. * Pregnant and lactating females. * Patients with acute renal insufficiency. * Face, flexural and groin lesions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Al-Hussien and cairo dermatology Hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.